Repurposing Clinically Safe Drugs to Guide DNA Repair Pathways in CRISPR Editing

Study Background and Research Question

DNA double-strand breaks (DSBs) are critical lesions that can arise spontaneously through metabolic stress or be intentionally introduced using programmable nucleases such as CRISPR-Cas9. The cellular response to DSBs depends on the activation of specific DNA repair pathways—primarily non-homologous end joining (NHEJ), microhomology-mediated end joining (MMEJ), and homologous recombination (HR) or homology-directed repair (HDR). These pathways differ in fidelity, mutational signatures, and suitability for precise genome engineering. However, controlling which pathway predominates at a given cut site remains a major challenge, limiting the predictability and safety of genome editing workflows. The reference study (Macak et al., 2025) aimed to address this challenge by identifying clinically approved drugs capable of shifting the balance of DNA repair pathway usage in human cells, with direct applications for CRISPR-based disease modeling, gene therapy, and targeted cancer treatment.

Key Innovation from the Reference Study

The central innovation of the study was an unbiased, high-throughput repurposing screen of over 7,000 FDA-approved drugs to systematically evaluate their effects on DSB repair pathway choice. By profiling mutational outcomes at CRISPR-induced DSBs in human induced pluripotent stem cells (hiPSCs), the authors identified compounds that can either inhibit or enhance the activity of NHEJ, MMEJ, or HDR. The work not only pinpointed pharmacological agents that fine-tune repair outcomes for more precise genome editing, but also revealed new synthetic lethality interactions exploitable for cancer therapy—where inhibiting compensatory repair pathways selectively kills repair-deficient tumor cells.

Methods and Experimental Design Insights

The experimental workflow began with the creation of hiPSC lines expressing a doxycycline-inducible Cas9 (iCRISPR system), enabling site-specific DSB induction at the FRMD7 locus during drug exposure. Each drug was applied in a single replicate across 7,240 conditions, followed by cell recovery, viability assessment via resazurin fluorescence, and deep sequencing to quantify DNA repair outcomes. Sequencing data were parsed to assign each repair event to NHEJ (typically short insertions), MMEJ (microhomology-driven deletions), or HDR (precise edits via exogenous donor templates).

In addition to drug screening, the study conducted genetic perturbation experiments—such as silencing of key repair regulators ESR2 and AOX1—to dissect pathway dependencies and uncover synergistic effects with pharmacological inhibitors. The workflow enabled a comprehensive mapping of drug-pathway interactions and their implications for both genome editing efficiency and cell survival under synthetic lethality paradigms.

Core Findings and Why They Matter

The screen revealed multiple drugs capable of modulating DSB repair outcomes. Key findings include:

• Identification of agents that selectively inhibit NHEJ or MMEJ, shifting repair toward HDR—a desirable outcome for precise, template-based genome editing. For example, combining ESR2 silencing with NHEJ inhibition increased HDR rates by a mean of 4.6-fold (reference study).
• Discovery of drug-induced synthetic lethality: certain compounds are toxic only when major repair pathways are genetically or pharmacologically blocked, highlighting candidates for selective cancer cell targeting.
• Evidence that pathway choice can be influenced not only by direct inhibitors (e.g., DNA-PKcs or PARP1 blockers) but also by modulating upstream regulators (such as ESR2 and AOX1) that interface with central DNA repair proteins like ATM and 53BP1.
• Confirmation that repair pathway modulation is quantifiable through mutational profiling at CRISPR cut sites, enabling predictable genome editing outcomes for disease modeling, gene correction, and cell therapy applications.

These insights expand the toolkit for genome engineers, providing a pharmacological route to boost the efficiency and precision of CRISPR-based interventions, while also informing therapeutic strategies that exploit repair vulnerabilities in cancer cells.

Comparison with Existing Internal Articles

Several internal resources address the utility of Dantrolene sodium salt as a ryanodine receptor antagonist in advanced research settings. For instance, the article "Dantrolene Sodium Salt: Precision Ryanodine Receptor Anta..." underscores its value for precision CRISPR genome editing and calcium signaling workflows. Similarly, "Dantrolene Sodium Salt: Precision Ryanodine Receptor Antagonist Workflows" details protocols for integrating this compound into DNA repair pathway studies. These articles highlight the importance of selective calcium modulation—particularly for researchers seeking to model neurodegenerative disease or ischemia—by leveraging Dantrolene's nanomolar potency and calmodulin-dependent mechanism. While the reference study focuses on DNA repair pathway pharmacology, the internal articles provide practical guidance for integrating ryanodine receptor antagonists like Dantrolene into similar cellular workflows, especially where calcium signaling intersects with genome stability or cellular stress responses.

Limitations and Transferability

The screening approach in the reference study is subject to several limitations:

• The use of a single CRISPR target site and hiPSC line may not capture repair dynamics in diverse genomic contexts or cell types.
• Most drug conditions were tested in single replicates, necessitating further validation for clinical translation.
• The observed synthetic lethality effects and pathway shifts may not extrapolate to in vivo disease models without additional pharmacokinetic and toxicity studies.
• Potential off-target effects of drugs were not exhaustively profiled.

Nevertheless, the core principle—that pharmacological modulation can rationally direct DNA repair outcomes—remains robust and transferable, especially in engineered cell systems or ex vivo gene editing protocols.

Protocol Parameters

• Drug treatment timing: Apply candidate modulators (identified in screening) during or immediately before CRISPR-induced DSB induction in target cells.
• Cell survival readout: Use fluorescence-based viability assays (e.g., resazurin) post-editing to assess synthetic lethality or cytotoxicity.
• Repair outcome profiling: Extract genomic DNA and perform high-throughput sequencing of target loci to quantify indel spectra and precise edits.
• Genetic perturbations: Combine pharmacological inhibition with siRNA or CRISPRi-mediated silencing of repair regulators (e.g., ESR2) to test for synergistic effects.
• Calcium signaling modulation (for cross-domain studies): When modeling the role of calcium flux in genome stability, use nanomolar concentrations of ryanodine receptor antagonists such as Dantrolene sodium salt as detailed in internal protocols.

Research Support Resources

For researchers aiming to integrate calcium signaling modulation into DNA repair or genome editing assays, Dantrolene, sodium salt (SKU B6329) from APExBIO offers a well-characterized, high-purity ryanodine receptor antagonist suitable for precise intracellular calcium control. As noted in internal articles, its nanomolar-range potency and calmodulin-dependent specificity support reproducible modeling of calcium-regulated processes, including in neurodegenerative disease or ischemia and hypoxia research settings. For protocol optimization and troubleshooting, consult the referenced internal guides for evidence-backed workflow enhancements.